Cambridge Healthtech Institute’s Inaugural

AI in Cancer Immunotherapy

August 7-8, 2023

Great progress has been made in studying cancer immunology and the development of immunotherapies. The complexity of the immune system and the duplicity of cancer, plus the expense of treatments and variable patient responses, make for a perfect data storm. Optimally utilizing and effectively handling these large data sets is daunting. Artificial intelligence (AI) and machine learning (ML) are poised to help unlock cancer’s secrets, identify and validate immuno-oncology (IO) targets, evaluate assets, and apply effective immunotherapies. The combined efforts of researchers, clinicians, and data scientists are required. Join colleagues to share strategies and celebrate successes at CHI’s Inaugural AI in Cancer Immunotherapy meeting.

Coverage will include, but is not limited to:

Data Sources

Patient “Omics”
Cancer “Omics”
Imaging
Markers of Response/Resistance
Tumor Microenvironment

IO Therapeutic Development

Target Validation

High-Throughput Platform Development

Lab-on-a-Chip
Microfluidics
Screening
3D Models
Translational Models

Computational Science

Applying Algorithms
AI/ML Training
Deep Learning
Biological Neural Networks
Models
Databases/Disparate Data Sources

Predicting Clinical Outcomes

Patient Response
Combination Therapies
Resistance

Case Studies

The deadline for priority consideration is February 3, 2023.

All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.

Opportunities for Participation: